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ABSTRACT
Introduction Literature is scarce on the combination 
treatment of ibrutinib and venetoclax (IV) is scarce in 
relapsed or refractory chronic lymphocytic leukaemia 
(RR- CLL). Especially, the possibility of stopping ibrutinib in 
RR- CLL patients in deep remission is unclear.
Methods and analysis In the HOVON 141/VISION trial, 
patients with RR- CLL are treated with 12 cycles of IV 
after a short induction with ibrutinib. Patients reaching 
undetectable minimal residual disease (uMRD) after 12 
cycles of IV are randomised 1:2 to continue ibrutinib or 
stop treatment. The persistence of uMRD after stopping IV 
is studied. In addition, in patients who become positive for 
MRD again after stopping, IV treatment is reinitiated. The 
efficacy of this approach with regard to progression- free 
survival 12 months after randomisation is the primary 
endpoint of the study.
Ethics and dissemination This protocol respects the 
Helsinki declaration and has been approved by the ethical 
committee of the Amsterdam Medical Center. Study 
findings will be disseminated through peer- reviewed 
papers. All patients who fulfil the inclusion criteria and no- 
exclusion criteria, and have signed the informed consent 
form are included in the study.
Trial registration number  ClinicalTrials. gov Registry 
(NCT03226301).
INTRODUCTION
The standard of care in treatment of patients 
with relapsed or refractory chronic lympho-
cytic leukaemia (RR- CLL) is rapidly changing. 
For patients with a relapse later than 2 years 
from first- line therapy, repeated therapy with 
a first- line or an alternative chemoimmuno-
therapy regimen has been regularly used.1 
Novel agents such as ibrutinib and venetoclax 
(IV) alone or in combination with anti- CD20 
antibodies are regularly used nowadays to 
treat relapse with high response rates. Ibru-
tinib treatment effectively targets the lymph 
node (LN) compartment but rarely results 
in deep clearance of peripheral blood (PB) 
and bone marrow (BM), which necessitates 
prolonged treatment with concomitant high 
costs and increasing rates of discontinuation 
due to either side effects2 or development of 
resistance.3 4 In contrast, venetoclax proved 
highly active in clearing CLL cells from blood 
and BM, but less so from LN.5 Treatment of 
relapse with a combination of rituximab and 
venetoclax demonstrated superior efficacy 
and less toxicity than rituximab and benda-
mustine.5 6 In addition, treatment with ibru-
tinib in patients with relapse demonstrated 
superior outcome in relation to ofatumumab.7
Strengths and limitations of this study
 ► Prospective intervention study of ibrutinib and vene-
toclax in chronic lymphocytic leukaemia.
 ► Primary study question on stopping ibrutinib in un-
detectable minimal residual disease patients.
 ► Central laboratory assessment of minimal residual 
disease (MRD) in only two academic laboratories.
 ► A randomised phase II study, but no phase III study.
 ► Safety measure of reinitiating treatment if patients 
become MRD positive.
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Data on IV are relatively limited. Recently, a first- line 
study revealed high response rates, and considerable and 
progressive minimal residual disease (MRD) negativity.8 
In addition, Rogers et al9 demonstrated activity and toler-
ability of IV (plus obinutuzumab) in RR- CLL patients in a 
phase I study. Very recently, Hillmen et al10 showed unde-
tectable MRD (uMRD) of blood in 28 (53%) and of BM in 
19 (36%) of 53 patients after 12 months of ibrutinib plus 
venetoclax, while 27 (51%) patients achieved a complete 
remission. Side effects were mild and manageable with 
one event of laboratory tumour lysis syndrome.
Preclinical data support the combination of the 
Bruton’s tyrosine kinase inhibitor ibrutinib and the B- cell 
lymphoma 2 inhibitor venetoclax by demonstrating 
synergy in a diffuse large B- cell lymphoma cell line 
model and in primary CLL cells, as well as in mantle cell 
lymphoma cell lines.11 Furthermore, several clinical trials 
are currently testing IV for clinical use, with no unex-
pected toxicities reported so far through scientific meet-
ings, publications or internal reports for the marketing 
holders. Consequently, the aim of the current trial is to 
evaluate if combination treatment with venetoclax+ibru-
tinib in patients with RR- CLL can lead to MRD negativity 
and induce long- lasting remission even after stopping the 
treatment.
METHODS AND ANALYSIS
Study aim
The aim of the current trial is to evaluate the progression- 
free survival (PFS) of patients with RR- CLL on combi-
nation treatment with IV. In addition, the persistence of 
uMRD after IV, which may induce long- lasting remission, 
is evaluated by randomising MRD- negative patients 2:1 
to stopping treatment after 15 cycles of induction or 
continuing ibrutinib.
Overall study design
Phase II trial, prospective, multicentre, open- label and 
randomised (online supplemental figure 1).
Patient population
Fit (Cumulative Illness Rating Scale (CIRS) ≤6) and unfit 
(CIRS >6) patients with a creatinine clearance ≥30 mL/
min with previously treated CLL, with or without TP53 
aberrations requiring treatment.12–14 For inclusion and 
exclusion criteria, see online supplemental tables 1 and 
2. On 23 January 2019, the last patient was included in the 
study. Randomisation is still ongoing.
Study design
This is a phase II study with late randomisation after cycle 
15 in MRD- negative patients on day 15 of cycle 15; no 
formal comparisons between the two randomised treat-
ment arms will be made (figure 1).
During the treatment period, all patients received 15 
cycles (28 days each) of oral ibrutinib. During the first two 
cycles, only ibrutinib 420 mg/day was administered. From 
day 1 in cycle 3, over 5 weeks, venetoclax was ramped up 
from 20 mg/day to the target of 400 mg/day, with vene-
toclax 400 mg/day administered for the remaining 12 
cycles.
Patients are followed by MRD assessment in PB at the 
end of cycle 9, end of cycle 12 and on day 15 of cycle 
15 (including BM), and thereafter, every 3 months for 
2 years, and every 4 months in the third year. MRD assess-
ment is performed by 8- colour flow cytometry according 
to the European Research Initiative on CLL guidelines.15 
Additional ror1 and CD45 antibodies are added to the 
panel; analysis by FACSDiva (BD Biosciences, San Jose, 
California, USA) at the two central laboratories for the 
trial. Gating strategies and flow cytometry settings are 
aligned and validated between the two laboratories by 
parallel analysis of samples.
Patients achieving uMRD (10–4 level by flow cytom-
etry)15 on day 15 of cycle 15 in PB and BM are randomised 
1:2 after completion of cycle 15 between continuous ibru-
tinib treatment until toxicity or progression (arm A) and 
treatment- free observation (arm B). An early amendment 
of the trial defined that it is not required to reach uMRD at 
the end of cycle 12 in PB to be eligible for randomisation. 
Patients not reaching MRD negativity in PB and/or BM 
at day 15 of cycle 15 continue ibrutinib treatment until 
toxicity or progression (non- randomised patients). This 
treatment is unblinded to patient and treating physician.
Patients with uMRD will be closely monitored for clin-
ical signs of relapse/progression along with 3- month 
MRD assessment for the first 2 years and 4- month MRD 
assessment in the third year after randomisation. Patients 
becoming MRD positive (defined as MRD ≥10–3 and at 
least 1 month later as MRD ≥10−2) or having symptomatic 
Figure 1 Scheme of treatment until cycle 15 and 
randomisation of MRD- negative patients. BM, bone marrow; 
MRD, minimal residual disease; neg, negative; PB, peripheral 
blood; pos, positive.
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CLL according to International Workshop on Chronic 
Lymphocytic Leukemia (IWCLL) criteria within the first 
3 years after randomisation, reinitiate treatment with 
IV for 12 cycles and continue ibrutinib treatment until 
toxicity or progression (figure 2).
Patients failing on reinitiation of therapy (not reaching 
any response (complete response/partial response/
stable disease) according to iwCLL criteria as assessed 
by the local investigator after three cycles of reinitiated 
therapy, or progressing within 12 months from randomi-
sation) are considered as having progressive disease and 
will go off protocol treatment.
Randomisation
Patients achieving uMRD on day 15 of cycle 15 (PB and 
BM) are randomised 1:2 after completion of cycle 15 
between continuous ibrutinib treatment until toxicity 
or progression, and treatment- free observation. Patients 
not reaching uMRD are not randomised and continue 
ibrutinib treatment until toxicity or progression. Rando-
misation has to occur within 14 days after MRD testing 
after day 15 of cycle 15. Patients need to be randomised 
through the electronic case report form (eCRF) system 
provided by the HOVON Data Center.
An amendment in the protocol was made to allow 
randomisation of patients who were not MRD negative at 
the end of cycle 12 in PB but became MRD negative (10–4 
level) at day 15 of cycle 15 (in PB and BM). Furthermore, 
this time point was moved 2 weeks in a prior amendment 
to allow for additional time for the MRD analysis prior to 
randomisation. These changes in protocol were based on 
an interim analysis demonstrating a significant number 
of patients meeting the MRD criterion at cycle 15, despite 
being MRD positive at the end of cycle 12.
PATIENT AND PUBLIC INVOLVEMENT
No patients or public were involved in the development 
and execution of this study.
PRIMARY STUDY OBJECTIVE
Evaluate efficacy of IV in terms of proportion of patients 
fulfilling the criteria for PFS at 12 months after stopping 
therapy (27 months after starting treatment) for those 
randomised to stop treatment (arm B of the study); reini-
tiating treatment due to MRD positivity is not considered 
progression. (figures 1 and 2).
For secondary study objectives and exploratory study 
objectives, see online supplemental table 3.
Data collection
Data will be collected on eCRFs to document eligibility, 
safety and efficacy parameters, compliance to treatment 
schedules and parameters necessary to evaluate the study 
endpoints. Data collected on the eCRF are derived from 
the protocol and will include at least:
 ► Inclusion and exclusion criteria.
 ► Baseline status of patient, including medical history 
and stage of disease.
 ► Timing and dosage of protocol treatment.
 ► Baseline concomitant diseases and adverse events.
 ► Parameters for response evaluation.
 ► Any other parameters necessary to evaluate the study 
endpoints.
 ► Survival status of patient.
 ► Reason for end of protocol treatment along with 
information about next line of therapy.
Monitoring
This trial is part of the HOVON Site Evaluation Visit 
programme. Site evaluation visits will be performed for 
HOVON trials to review the quality of the site and not 
specifically the quality of a certain trial. It will enable 
HOVON to collect quality data and facilitate improve-
ment of the participating sites. Data cleaning or moni-
toring of the performance of specific trials is not the goal 
Figure 2 Scheme of reinduction treatment of MRD- negative 
patients after cycle 15 turning MRD positive after treatment 
cessation. CLL, chronic lymphocytic leukaemia; iwCLL, 
International Workshop on Chronic Lymphocytic Leukemia; 
MRD, minimal residual disease.
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of the site evaluation visits. Site evaluation visits will be 
performed according to the site evaluation visit plan. The 
HOVON site evaluation visit plan applies to sites in the 
Netherlands, Belgium and Luxembourg only. Monitoring 
of the quality of trial conducted in participating sites 
from other countries will be organised by the national 
coordinating investigator or co- sponsor. The frequency 
and content of the site visits in other countries will be at 
least equal to the specifications of the site evaluation visit 
plan, and are described in a monitoring plan provided by 
HOVON.
DATA STATEMENT
Al data are gathered in ALEA, the data capturing system 
used by the HOVON. All data are registered in this elec-
tronic data capturing system by local data managers of all 
sites.
STATISTICS
Efficacy analysis
The PFS primary endpoint will be analysed as soon as all 
randomised patients have achieved the landmark of 12 
months after randomisation. Thus, final analysis will take 
place as soon as the last patient starting treatment has 
reached the time point of month 27 and data have been 
assembled from all study sites. Given an estimated 3- year 
recruitment period, the time point of final PFS analysis is 
projected to be 5 years and 6 months after initiation of trial.
The primary efficacy endpoint is the investigator- 
assessed proportion of patients with PFS at month 27 in 
arm B (observation arm), the intention- to- treat popula-
tion for arm B is used for calculation of the proportion. 
PFS is defined as all patients free of progression or relapse 
(determined using standard IWCLL guidelines (2008)) 
or death from any cause, whichever occurs first. Patients 
in the observation arm becoming MRD positive, and thus 
restarting treatment, are still considered progression- free as 
long as they do not progress according to IWCLL criteria 
after reinitiation of treatment. If patients in the observation 
arm have clinical progression but achieve response within 
3 months of reinitiating treatment, they are still considered 
progression- free. Patients reinitiating therapy prior to the 
12- month time point from randomisation according to the 
rules outlined above, who have progressed according to 
IWCLL criteria before reinitiating treatment, are allowed 
up to 3 months to obtain response after reinitiating therapy. 
These patients will be considered progression- free at month 
27 if a response is achieved within 3 months from reiniti-
ating therapy.
Power calculation
The primary objective of the study is to test the following 
hypothesis: the PFS rate at 12 months after randomisation 
for the observation arm (B) is more than 60% (ie, H0: 
PFS rate at 12 months post randomisation ≤60% vs H1: 
PFS rate at 12 months post randomisation >60%). PFS 
and the 95% CI will be estimated using the Kaplan- Meier 
survival methodology, and a Kaplan- Meier survival curve 
will be generated to provide a visual illustration of PFS for 
patients in the different treatment arms separately (from 
randomisation), and also for all patients together (from 
registration).
Target number of patients—207 eligible patients. 
However, in order to take into account possible dropout 
due to ineligibility, 230 patients will be registered.
Only patients randomised for observation (arm B) 
are considered for the primary endpoint without formal 
comparison between the arms.
Before the final analysis, a statistical analysis plan will 
be prepared by the trial statistician and approved by the 
principal investigator. It will describe in detail the analyses 
to be performed. Deviations from the analyses, as speci-
fied above, will be discussed with the study coordinators 
and can only affect the exploratory analyses, but not the 
primary (confirmatory) analysis on which the sample size 
is based. All analyses, except the primary analysis, should 
be considered as hypothesis- generating only.
Interim analyses
See online supplemental table 4.
The results of the interim analyses will be reviewed 
by the Data Safety and Monitoring Board (DSMB) 
and, if necessary, additional analyses can be performed 
depending on the request of the DSMB.
ETHICS AND DISSEMINATION
This protocol respects the Helsinki declaration and has 
been approved by the ethical committee of the Amsterdam 
Medical Center. All patients will provide written informed 
consent (online supplemental figure 2).
Trial results will be submitted for publication in a peer- 
reviewed scientific journal regardless of the outcome of the 
trial, unless the trial was terminated prematurely and did not 
yield sufficient data for publication. Interim analyses will be 
presented at scientific meetings and may be submitted for 
publication in peer- reviewed scientific journals.
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